U.S. Markets closed

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
33.96-0.41 (-1.19%)
At close: 4:00PM EDT
People also watch
Interactive chart
Previous Close34.37
Bid0.00 x
Ask0.00 x
Day's Range33.95 - 34.26
52 Week Range25.25 - 36.82
Avg. Volume1,036,450
Market Cap224.4B
PE Ratio (TTM)24.24
Earnings DateN/A
Dividend & Yield1.03 (3.03%)
Ex-Dividend Date2017-03-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters3 hours ago

    UPDATE 1-Deadly brain infection in German MS patient prompts Roche investigation

    A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year, the Swiss drugmaker said on Wednesday. Roche said it was investigating a case of Progressive Multifocal Leukoencephalopathy (PML) in a patient previously being treated for three years with Biogen Inc's Tysabri and who had received a single dose of Ocrevus in April. Roche is trying to determine the source of the illness but MS drugs that suppress the immune system can increase the risk of serious infections.

  • Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet
    Zacks2 days ago

    Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet

    Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet.

  • Market Realist2 days ago

    Nplate and Vectibix Could Contribute to Amgen’s Revenue Growth in 2017

    In 1Q17, Amgen’s (AMGN) Nplate generated revenues of ~$154 million, which reflected a year-over-year growth rate of 9%.